Phase 1 biotech developing precision antibody therapies for IBD and related diseases.
Industry: Health Care
First Day Return: +33.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 02/19/2021 |
Offer Price | $19.00 |
Price Range $18.00 - $19.00 | |
Offer Shares (mm) | 10.0 |
Deal Size ($mm) | $190 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 03/11/2021 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $190 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | San Diego, CA, United States |
Founded | 2016 |
Employees at IPO | 27 |
Website www.prometheusbiosciences.com |